Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Tumors With cKIT Mutations (MATCH Subprotocol V)
NCT06390826Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2016
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sunitinib in malignant solid neoplasm, refractory malignant solid neoplasm, lymphoma, multiple myeloma (MM), sponsored by National Cancer Institute. Started Nov 2016; status: active, not recruiting.
02
Drugs
sunitinib
03
Conditions
malignant solid neoplasmrefractory malignant solid neoplasmlymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT06390826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06390826.